BPC-157 cost: what a prescription costs, and what research-grade vials lack
Published prices by program type, checked November 2, 2026. REMEVi does not currently price BPC-157.
Few programs publish a price for compounded BPC-157, and those that do structure it differently: per month, per cycle, or as a membership with medication billed separately. REMEVi does not currently price or offer BPC-157. Below: what published programs list, what the 2026 policy’s sourcing rules add, and why research-grade vials cost less.
BPC-157 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer BPC-157.
What compounded BPC-157 costs, by program type
| Program type | Published price | What the price covers |
|---|---|---|
| Telehealth peptide programs | From $105 per month (injectable vial) to $149 per month (membership with a blood panel; medication billed separately) | One page lists a starting price without itemizing; the other charges medication up front on top of the membership |
| Clinic hormone and wellness programs | $445 per one-month cycle, or $307.50 per month on a six-cycle plan; $150 consult deposit credited toward treatment | Compounded medication and a consultation with a licensed provider, per the clinic’s page (prices stated as current from May 2026) |
| Research-grade vials | Not listed here (checked 2026-11-02) | Sold labelled for research use, outside the 2026 policy; this page does not link to those sellers |
Prices are what each publisher posted on the date checked. They change, they may predate the October 2026 policy, and they are not REMEVi prices. Publishers are named in the sources list.
What the CoA and registered-source requirements add
Under HHS’s 2026 policy, a compounded BPC-157 prescription carries steps a research vial skips:
- Bulk BPC-157 from an FDA-registered facility with a valid certificate of analysis, from a manufacturer that is FDA-registered and CGMP-compliant.
- Compounding by a state-licensed 503A pharmacy for one named patient, one active ingredient per product.
- Oral forms: documentation that the formulation is adequately bioavailable in humans.
- A labelled product (“This is a compounded drug product. Not for resale.”) and a 510(k)-cleared syringe as the one packaged device.
- A prescriber’s evaluation, and serious adverse events reported to FDA MedWatch.
Each step is documentation, testing or clinical time, which is part of why a prescription costs more than a vial.
Why research-grade BPC-157 is cheaper, and what it lacks
Research-use vials skip the prescriber, the pharmacy and the paperwork. What you give up:
- No prescription and no evaluation of whether it is appropriate for you.
- No licensed pharmacy answerable for identity, strength or sterility.
- No certificate of analysis tied to an FDA-registered source.
- No patient label, and no adverse-event reporting path.
- No coverage under the 2026 policy. FDA sent warning letters to five online peptide vendors on August 24, 2026.
REMEVi does not currently price BPC-157
REMEVi does not offer BPC-157 and has no BPC-157 price. What REMEVi does offer uses the same prescription-and-licensed-pharmacy model:
How much does BPC-157 cost per month?
Few programs publish one. On November 2, 2026, telehealth programs we checked listed starting monthly prices in the low hundreds of dollars, sometimes with medication billed separately, and one clinic priced it per one-month cycle. Prices exclude research-use vials, which the 2026 policy does not cover. REMEVi does not currently price BPC-157.
Sources
- HealthRX — BPC-157 cost per month (program card “Injectable vial · From … /mo”) (read November 2, 2026)
- Superpower — BPC-157 (membership price; medication charged separately) (read November 2, 2026)
- Perfect B Aesthetic Medicine (Doral, FL) — How much does BPC-157 cost? (updated Oct 13 2026; prices stated current as of May 2026) (read November 2, 2026)
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
- Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Holland & Knight, Oct 16 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·